Tourmaline Bio price target raised to $43 from $42 at Wedbush
Wedbush raised the firm’s price target on Tourmaline Bio (TRML) to $43 from $42 and keeps an Outperform rating on the shares. All key ...
Tourmaline Bio (TRML) Gets a Buy from Wedbush
In a report released today, Laura Chico from Wedbush maintained a Buy rating on Tourmaline Bio (TRML – Research Report), with a price target of ...